A case-control study using deidentified patient health information from a large database set of commercially insured US population, that identified 30,772 patients treated with TNF-ɑ inhibitors for autoimmune diseases (unspecified underlying disease), from January 2007 to December 2009. Here, TNF is linked to autoimmune disease.